Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2009 | Research

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer

Authors: Weiguo Sui, Minglin Ou, Jiejing Chen, Youhua Wan, Hongbo Peng, Minfang Qi, He Huang, Yong Dai

Published in: World Journal of Surgical Oncology | Issue 1/2009

Abstract

Background

The concordance rate between IHC and FISH according to clinical performance is still controversial. We report a prospective study to reflect the concordance between IHC and FISH in Guilin city, People's Republic of China.

Methods

Fifty cases of invasive ductal carcinoma of breast tested by IHC and scored as 0, 1+, 2+ and 3+ by pathologists were further analyzed by FISH using a commercially available double-color probe, and the FISH findings were compared with IHC test results.

Results

A total concordance of 82.0% was observed with a Kappa coefficient of 0.640 (P < 0.001). A high discordance was observed in 30.0% of the patients with IHC 2+, 7.1% in IHC 3+, 19.2% overall in IHC 0 and 1+.

Conclusion

The IHC can be used firstly to screen the HER-2 status, and FISH can be used as a supplementary role to IHC and 2+ and some negative cases. And only those cases with Her-2 status of IHC 3+ or FISH positive should be treated with Herceptin.

Available only for authorised users

Parkin DM, Bray F, Ferlay J: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55 (2): 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed

Zheng Y, Li DL, Xiang YM, Li XJ: The status and trend of breast cancer incidence in Shanghai. J Surg Concepts Pract. 2001, 6: 219-221.

Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991, 51 (2): 556-67.PubMed

Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol. 1993, 11 (10): 1936-42.PubMed

Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R: Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993, 53 (20): 4960-70.PubMed

Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997, 15 (8): 2894-904.PubMed

Ross JS, Fletcher JA: The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999, 9 (2): 125-38. 10.1006/scbi.1998.0083.CrossRefPubMed

Dean-Colomb W, Esteva FJ: Her2-positive breast cancer: herceptin and beyond. Eur J Cancer. 2008, 44 (18): 2806-12. 10.1016/j.ejca.2008.09.013.CrossRefPubMed

Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J: Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000, 157 (5): 1467-72.PubMedCentralCrossRefPubMed

10.

Sáez A, Andreu FJ, Seguí MA, Baré ML, Fernández S, Dinarés C, Rey M: HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases. Breast. 2006, 15 (4): 519-27. 10.1016/j.breast.2005.09.008.CrossRefPubMed

11.

Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Nesland JM: The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer. 2000, 88 (4): 804-13. 10.1002/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-Y.CrossRefPubMed

12.

Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000, 18 (21): 3651-64.PubMed

13.

Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001, 19 (10): 2714-21.PubMed

14.

Wolff AC, Hammond EH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25 (1): 118-45. 10.1200/JCO.2006.09.2775.CrossRefPubMed

15.

Dolan M, Snover D: Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol. 2005, 123 (5): 766-70. 10.1309/Q0DGL26RUCK1K5EV.CrossRefPubMed

16.

Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer. 2002, 95 (7): 1592-600. 10.1002/cncr.10854.CrossRefPubMed

17.

Bempt Vanden I, Vanhentenrijk V, Drijkoningen M, Vandenberghe P, De WC: Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology. 2005, 46 (4): 431-41. 10.1111/j.1365-2559.2005.02112.x.CrossRef

18.

Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004, 5 (1): 63-9. 10.3816/CBC.2004.n.011.CrossRefPubMed

19.

Dybdal N, Leiberman G, Anderson S: Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat. 2005, 93 (1): 3-11. 10.1007/s10549-004-6275-8.CrossRefPubMed

20.

Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005, 6 (3): 240-6. 10.3816/CBC.2005.n.026.CrossRefPubMed

21.

Lan C, Liu JM, Liu TW, Hsu D, Liang S, Chen JR, Peng JW: Erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. Am J Clin Pathol. 2005, 124 (1): 97-102. 10.1309/R2X4KK22QCL7PLME.CrossRefPubMed

22.

Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M: Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients. Taiwan J Obstet Gynecol. 2007, 46 (2): 146-51. 10.1016/S1028-4559(07)60008-4.CrossRefPubMed

23.

Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol. 2000, 113 (2): 251-8. 10.1309/980M-E24R-V19K-595D.CrossRefPubMed

Title: Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
Authors: Weiguo Sui
Minglin Ou
Jiejing Chen
Youhua Wan
Hongbo Peng
Minfang Qi
He Huang
Yong Dai
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2009
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-7-83

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Genomic and oncoproteomic advances in detection and treatment of colorectal cancer

Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance

Pancreatic insulinoma co-existing with gastric GIST in the absence of neurofibromatosis-1

Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer

Intradural squamous cell carcinoma in the sacrum

Primary hepatic embryonal sarcoma masquerading as metastatic ovarian cancer